On April 6, 2022 (the Effective Date"), Prelude Therapeutics Incorporated and Deborah Morosini, the Company's EVP and Chief of Clinical Affairs, agreed that, effective as of the Effective Date, Dr. Morosini shall resign from her role as an officer of the Company and will transition into a role of Strategic Advisor to the President from the Effective Date until May 5, 2022, upon which Dr. Morosini's employment with the Company shall terminate (the Separation Date").